Immunodetection of NKX2‐1 in combination with NAPSA and immunonegativity of TP63 is sufficient to distinguish ADC among the other NSCLC subtypes (Noh & Shim, 2012). This evidence concerns the gene NKX2-1 and non-small cell lung carcinoma.